Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/124594
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Activation of DREAM (Downstream Regulatory Element Antagonistic Modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice

AutorRuiz de Diego, Irene CSIC ORCID; Mellström, Britt CSIC; Vallejo, Mario CSIC ORCID; Naranjo, José Ramón CSIC ORCID; Moratalla, Rosario CSIC ORCID
Fecha de publicación2015
EditorElsevier
CitaciónBiological Psychiatry 77(2): 95-105 (2015)
Resumen[Background]: Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well as FosB and dynorphin-B expression mediated by dopamine D1 receptor stimulation in the development of 3,4-dihydroxyphenyl-L-alanine (L-DOPA)–induced dyskinesia. The magnitude of these molecular changes correlates with the intensity of dyskinesias. The calcium-binding protein downstream regulatory element antagonistic modulator (DREAM) binds to regulatory element sites called DRE in the DNA and represses transcription of target genes such as c-fos, fos-related antigen-2 (fra-2), and prodynorphin. This repression is released by calcium and protein kinase A activation. Dominant-active DREAM transgenic mice (daDREAM) and DREAM knockout mice (DREAM−/−) were used to define the involvement of DREAM in dyskinesias. [Methods]: Dyskinesias were evaluated twice a week in mice with 6-hydroxydopamine lesions during long-term L-DOPA (25 mg/kg) treatment. The impact of DREAM on L-DOPA efficacy was evaluated using the rotarod and the cylinder test after the establishment of dyskinesia and the molecular changes by immunohistochemistry and Western blot.
[Results]: In daDREAM mice, L-DOPA-induced dyskinesia was decreased throughout the entire treatment. In correlation with these behavioral results, daDREAM mice showed a decrease in FosB, phosphoacetylated histone H3, dynorphin-B, and phosphorylated glutamate receptor subunit, type 1 expression. Conversely, genetic inactivation of DREAM potentiated the intensity of dyskinesia, and DREAM−/− mice exhibited an increase in expression of molecular markers associated with dyskinesias. The DREAM modifications did not affect the kinetic profile or antiparkinsonian efficacy of L-DOPA therapy. [Conclusions]: The protein DREAM decreases development of L-DOPA-induced dyskinesia in mice and reduces L-DOPA-induced expression of FosB, phosphoacetylated histone H3, and dynorphin-B in the striatum. These data suggest that therapeutic approaches that activate DREAM may be useful to alleviate L-DOPA-induced dyskinesia without interfering with the therapeutic motor effects of L-DOPA.
Versión del editorhttps://doi.org/10.1016/j.biopsych.2014.03.023
URIhttp://hdl.handle.net/10261/124594
DOI10.1016/j.biopsych.2014.03.023
Identificadoresdoi: 10.1016/j.biopsych.2014.03.023
issn: 0006-3223
e-issn: 1873-2402
Aparece en las colecciones: (IIBM) Artículos
(IC) Artículos
(CNB) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
ActivationDREAM.pdf1,56 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

49
checked on 14-mar-2024

WEB OF SCIENCETM
Citations

48
checked on 22-feb-2024

Page view(s)

303
checked on 18-mar-2024

Download(s)

648
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.